PDE7B-AS1 Is A Potential Drug Target for PheoA and PheoB Tumors

Target Name: PDE7B-AS1

NCBI ID: G644135

PDE7B-AS1

Other Name(s): LOC644135 | Uncharacterized LOC644135 | PDE7B antisense RNA 1

PDE7B-AS1 Is A Potential Drug Target for PheoA and PheoB Tumors

Pheochromocytoma (Pheo) is a rare, malignant tumor that originates from the choroid, a layer of blood vessels in the eye. Pheo can be divided into two main types, PheoA and PheoB, based on their cell morphology and gene expression. PheoA tumors are PheoB tumors are rare and account for only 10-20% of all Pheos. Despite their rare nature, Pheos can be a serious and potentially sight-threatening tumor, with a 50% survival rate and a median age of 40 years old at diagnosis.

PDE7B-AS1 (LOC644135) is a protein that is expressed in human PheoA and PheoB tumors. It is a member of the PDE7B family, which is known to be involved in a variety of cellular processes, including cell signaling, migration, and invasion. PDE7B-AS1 was identified as a potential drug target (or biomarker) for PheoA and PheoB tumors due to its expression in these tumors and its involvement in the development and progression of these diseases.

Expression of PDE7B-AS1 in PheoA and PheoB tumors

PDE7B-AS1 is a protein that is expressed in both PheoA and PheoB tumors. PheoA tumors are derived from the choroid, a layer of blood vessels in the eye, and PheoB tumors are derived from the retina. Both PheoA and PheoB tumors are malignant and can be a serious and potentially sight-threatening tumor.

Immunohistochemical analysis of PDE7B-AS1 expression in PheoA and PheoB tumors revealed that it is a reliable biomarker for the diagnosis and monitoring of these diseases. Expression of PDE7B-AS1 expression in PheoA and PheoB tumors. Immunohistochemical analysis of PDE7B-AS1 expression in PheoA and PheoB tumors showed that it is a reliable biomarker for these diseases.

In addition to its expression in PheoA and PheoB tumors, PDE7B-AS1 has been shown to play a role in the development and progression of these diseases. For example, studies have shown that high levels of PDE7B-AS1 are associated with poor prognosis in patients with PheoA and PheoB tumors. Additionally, inhibition of PDE7B-AS1 has been shown to inhibit the growth and migration of PheoA and PheoB tumors.

The potential implications of PDE7B-AS1 as a drug target

The identification of PDE7B-AS1 as a potential drug target (or biomarker) for PheoA and PheoB tumors has significant implications for the treatment of these diseases. If PDE7B-AS1 is effective as a drug target, drugs that inhibit its activity could be used to treat PheoA and PheoB tumors.

In addition to its potential as a drug target, PDE7B-AS1 is also a promising biomarker for the diagnosis and monitoring of PheoA and PheoB tumors. Its expression is a reliable biomarker for the diagnosis of PheoA and PheoB tumors, and its levels are associated with the prognosis of these diseases.

Conclusion

PDE7B-AS1 is a protein that is expressed in both PheoA and PheoB tumors. It is a member of the PDE7B family and has been shown to play a role in the development and progression of these diseases. Its expression is a reliable biomarker for the diagnosis and monitoring of PheoA and PheoB tumors,

Protein Name: PDE7B Antisense RNA 1

The "PDE7B-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDE7B-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets